Genomic Tests For Warfarin Could Gain Coverage With Study Participation
This article was originally published in The Gray Sheet
Executive Summary
CMS wants more evidence that genetic testing of individuals' responsiveness to the blood thinner warfarin actually improves health outcomes in Medicare populations, and the agency is using the national coverage process to call for randomized clinical trials
You may also be interested in...
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Medicare will only cover genetic testing for individual response to the blood-thinner warfarin in the context of controlled clinical studies, effective immediately, CMS said Aug. 3
CMS Will Cover Warfarin Gene Tests In Clinical Trials, But That's It
Data suggesting some link between CYP2C9 or VKORC1 gene mutations and a patient's likelihood of fatal excessive bleeding in response to the drug are enough for a coverage-with-evidence-development policy, where beneficiaries enrolled in qualifying trials are covered.